'The right leader at the right time': Noninvasix appoints David J. Giarracco as CEO

A Galveston-based non-invasive technology for monitoring the oxygenation of veins recently announced that they were under new leadership.

Last week, Noninvasix stated that David J. Giarracco will be the company’s new CEO.

Dr. Tom Luby said that Giarracco will help lead the company in its objective and play a crucial role in bringing down associated health care costs.

“Dave is the right leader at the right time for Noninvasix. He has a deep understanding of launching new platform technologies that make a critical difference in patient safety and clinical outcomes while reducing overall health care costs,” Luby said.

Giarracco has previous experience as a medical device executive and will help advertise the only non-invasive patient monitoring device designed for earlier detection of life-threatening sepsis, according to Noninvasix.

Giarracco said that efficient strategies for mitigating sepsis infections are greatly needed.

“Prevention and control strategies for sepsis infections are urgently needed,” he said. “We need new, non-invasive approaches for early diagnosis to reduce complications and save lives. Noninvasix technology promises to make a major difference in patient care, reduce health care costs and have wider applications beyond sepsis.”

Giarracco was previously the head of Medtronic and Covidien and obtained a bachelor's degree from Johns Hopkins University and a master's degree from the Johns Hopkins School of Medicine.

Throughout his career, Giarracco has cultivated a 25-year career in the medical technology industry, according to Noninvasix.

“Dave will play an essential role in helping refine our strategy and drive product development activity to realize our mission of better detecting and monitoring sepsis,” said Dr. Donald Prough, Rebecca Terry White distinguished professor and chairman of the Department of Anesthesia at the University of Texas Medical Branch. “As a Noninvasix founder and practicing anesthesiologist, I am excited about our future and the opportunity to make a significant impact on this major healthcare challenge.”

According to a press release, the company hopes to monitor the severity of sepsis and septic shock without surgery, “enabling clinicians to diagnose and monitor the response to treatment of tissue hypoxia in real-time.”